Nanobiotix Says JNJ-1900 (NBTXR3) Shows 61% One-Year Local Progression-Free Survival And 70% One-Year Overall Survival In Phase 1 NSCLC Trial
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year
Nanobiotix tested a new cancer medicine on 24 patients. All finished safely, and most stayed healthy one year later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.